Content about Pharmaceutics

January 10, 2010

Sanofi-Aventis is the latest pharma powerhouse to make the move toward over-the-counter medicine with its...

January 7, 2010

A biopharmaceutical company announced the resignation of one of its executives....

January 7, 2010

Watson Labs, a subsidiary of specialty pharmaceutical company Watson Pharmaceuticals, has filed an abbreviated new...

January 6, 2010

A privately held drug development company announced the closure of its acquisition by Eisai for...

January 6, 2010

GlaxoSmithKline will be underwriting a weight-loss/eating documentary in partnership with the Creative Coalition, an advocacy...

January 5, 2010

The Food and Drug Administration approved 26 drugs in 2009, compared with 25 approvals in 2008....

January 4, 2010

A maker of generic injectable drugs is involved in a patent infringement suit over a...

January 4, 2010

An India drug maker is in generic drug supply talks with two companies, according to...

January 3, 2010

The Food and Drug Administration has requested additional information and recommended additional clinical studies be...

January 3, 2010

Novartis is looking to purchase the remaining shares in an eye care company....

January 3, 2010

A generic drug maker has announced the availability of a treatment of the signs and...

December 20, 2009

This is further substantiation that the business of over-the-counter medicines, particularly those sold in the...

NEW YORK This is further substantiation that the business of over-the-counter medicines, particularly those sold in the U.S. market, is a key growth driver for pharma companies. If you weren’t convinced when Pfizer re-entered the OTC market with its acquisition of Wyeth, then you certainly should be convinced now.

 

March 12, 2009

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies....

The last few weeks have seen a lot of acquisition activity among large pharmaceutical companies.

 

First, Pfizer announced in January that it would acquire Wyeth for approximately $68 billion. This month saw three more mergers: Merck & Co.’s $41.1 billion purchase of Schering-Plough Corp., Roche’s $46.8 billion purchase of Genentech and Gilead Science’s purchase of CV Therapeutics.

 

January 11, 2009

Par Pharmaceutical Cos. had total sales of $291.9 million and $26.3 million in profit for...

November 10, 2008

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry. Between this year and 2016, $131 billion worth of drugs will come off patent, followed by a long decline often called the patent cliff. Facing this precipice, generic drug companies will have to adapt as the market becomes increasingly commoditized.

The situation is like having plans to bake a loaf of bread for dinner, but discovering at 5 p.m. that the flour is running low, and there is little time to go to the supermarket to buy more. Generic drug makers depend on a steady supply of expiring patents coming from large pharmaceutical companies for their business. In recent years, a whole slew of blockbuster drugs have come off patent, allowing generic drug makers to lap up the drug compounds. Over the next several years, however, the supply of expiring patents will begin to run dry.

September 19, 2007

Hi-Tech Pharmaceuticals has received final approval from the Food and Drug Administration for its application...

September 19, 2007

Teva is introducing its generic to the Sanofi-Aventis anti-fungal medication Penlac nail lacquer....